Replies to post #29 on PharmaGap fka GAP

[Tackler]

PharmaGap Inc. is a biotechnology company with a core focus designing and developing novel
therapeutic drugs for the treatment of cancer and other human diseases associated with the human
Protein Kinase C enzyme (“PKC”). Founded in 1999, the Company is a spin-off from Canada’s preeminent
biological research organization, the National Research Council (NRC).
Using its proprietary drug development platform, the Company is developing a pipeline of novel
compounds targeting PKC. PKC is often expressed in abnormal levels in many types of cancer and other
diseases, such as diabetes.
PharmaGap’s lead drug compound, PhGα1, is currently in the pre-clinical testing stage and has shown in
vitro and in vivo efficacy in selected cancer types. The Company is actively seeking capital and seeking a
business collaboration with other companies in the business of pharmaceutical development, including
licensing arrangements and other business arrangements including but not limited to a sale of the
Company or its assets, merger, or joint ventures.
The Company’s business strategy is to license its drug compounds to third parties for completion of
human trials and subsequent commercialization in return for initial license payments, milestone payments
as the compounds progress through clinical trials, and, in the event the compound reaches the point of
clinical sales, royalties on sales of the compound. There is no assurance as to the realization, form or
size of any of these potential payments in the future.